The Journal of Immunology, Vol 153, Issue 11 5167-5175, Copyright © 1994 by American Association of Immunologists

ARTICLES

IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis

L Romani, A Mencacci, L Tonnetti, R Spaccapelo, E Cenci, P Puccetti, SF Wolf and F Bistoni
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.

In murine models of systemic candidiasis, healing and nonhealing patterns of disease are associated with preferential expansion of Th1 and Th2 cells, respectively. As previous studies have shown IL-12 to be expressed transcriptionally in healer mice and to be required for Th1 development in vitro, this cytokine might play a role in Candida-driven Th1 cell differentiation in vivo. In the present study, IL-12- neutralizing Abs or recombinant IL-12 were administered to mice with healing or progressive candidiasis, respectively, and the animals were monitored for mortality, resistance to reinfection, serum levels of specific Abs, and IFN-gamma, IL-4, and IL-10 message/protein expression by CD4+ cells. In self-limiting infection by a yeast vaccine strain, neutralization of IL-12 ablated development of acquired anticandidal resistance and led to appearance of Candida-specific IgE and IL-4- producing cells. In mice with progressive systemic disease as well as in a mucosal infection model, administration of IL-12 did not result in therapeutic activity under conditions of yeast infection that would instead be resolved by serologic ablation of IL-4 or IL-10. Yet, in systemically infected mice cured by anti-IL-4 or anti-IL-10 therapy, the emergence of a Th1 response correlated with the detection of high levels of circulating IL-12 and splenic IL-12 transcripts. Although exogenous IL-12 may not be sufficient for Th conversion in the presence of an overwhelming IL-4/IL-10 response, endogenous production of IL-12 may be both required and prognostic for Th1 differentiation in vivo.

This article has been cited by other articles:

				L. J Ma, E. A Guzman, A. DeGuzman, H K. Muller, A. M Walker, and L. B Owen Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement J. Endocrinol., May 1, 2007; 193(2): 291 - 297. [Abstract] [Full Text] [PDF]

				J. Kosonen, A. Rantala, C. H. Little, P. Lintu, P.-R. Harjamaki, G. M. Georgiou, R. E. Cone, and J. Savolainen Increased Levels of Candida albicans Mannan-Specific T-Cell-Derived Antigen Binding Molecules in Patients with Invasive Candidiasis Clin. Vaccine Immunol., April 1, 2006; 13(4): 467 - 474. [Abstract] [Full Text] [PDF]

				A. S. Ibrahim, B. J. Spellberg, V. Avenissian, Y. Fu, S. G. Filler, and J. E. Edwards Jr. Vaccination with Recombinant N-Terminal Domain of Als1p Improves Survival during Murine Disseminated Candidiasis by Enhancing Cell-Mediated, Not Humoral, Immunity Infect. Immun., February 1, 2005; 73(2): 999 - 1005. [Abstract] [Full Text] [PDF]

				B. Spellberg, D. Johnston, Q. T. Phan, J. E. Edwards Jr., S. W. French, A. S. Ibrahim, and S. G. Filler Parenchymal Organ, and Not Splenic, Immunity Correlates with Host Survival during Disseminated Candidiasis Infect. Immun., October 1, 2003; 71(10): 5756 - 5764. [Abstract] [Full Text] [PDF]

				J. J. Gaforio, E. Ortega, I. Algarra, M. J. Serrano, and G. Alvarez de Cienfuegos NK Cells Mediate Increase of Phagocytic Activity but Not of Proinflammatory Cytokine (Interleukin-6 [IL-6], Tumor Necrosis Factor Alpha, and IL-12) Production Elicited in Splenic Macrophages by Tilorone Treatment of Mice during Acute Systemic Candidiasis Clin. Vaccine Immunol., November 1, 2002; 9(6): 1282 - 1294. [Abstract] [Full Text] [PDF]

				C. A. Salkowski, K. Kopydlowski, J. Blanco, M. J. Cody, R. McNally, and S. N. Vogel IL-12 Is Dysregulated in Macrophages from IRF-1 and IRF-2 Knockout Mice J. Immunol., August 1, 1999; 163(3): 1529 - 1536. [Abstract] [Full Text] [PDF]

				H. Kobayashi, M. Kobayashi, T. Utsunomiya, D. N. Herndon, R. B. Pollard, and F. Suzuki Therapeutic Protective Effects of IL-12 Combined with Soluble IL-4 Receptor Against Established Infections of Herpes Simplex Virus Type 1 in Thermally Injured Mice J. Immunol., June 15, 1999; 162(12): 7148 - 7154. [Abstract] [Full Text] [PDF]

				M. Marinaro, P. N. Boyaka, R. J. Jackson, F. D. Finkelman, H. Kiyono, E. Jirillo, and J. R. McGhee Use of Intranasal IL-12 to Target Predominantly Th1 Responses to Nasal and Th2 Responses to Oral Vaccines Given with Cholera Toxin J. Immunol., January 1, 1999; 162(1): 114 - 121. [Abstract] [Full Text] [PDF]

				A. Mencacci, E. Cenci, G. D. Sero, C. Fe d'Ostiani, P. Mosci, G. Trinchieri, L. Adorini, and L. Romani IL-10 Is Required for Development of Protective Th1 Responses in IL-12-Deficient Mice upon Candida albicans Infection J. Immunol., December 1, 1998; 161(11): 6228 - 6237. [Abstract] [Full Text] [PDF]

				E. Cenci, A. Mencacci, G. Del Sero, C. Fe d'Ostiani, P. Mosci, A. Bacci, C. Montagnoli, M. Kopf, and L. Romani IFN-{gamma} Is Required for IL-12 Responsiveness in Mice with Candida albicans Infection J. Immunol., October 1, 1998; 161(7): 3543 - 3550. [Abstract] [Full Text] [PDF]

				A. Mencacci, G. Del Sero, E. Cenci, C. F. d'Ostiani, A. Bacci, C. Montagnoli, M. Kopf, and L. Romani Endogenous Interleukin 4 Is Required for Development of Protective CD4+ T Helper Type 1 Cell Responses to Candida albicans J. Exp. Med., February 2, 1998; 187(3): 307 - 317. [Abstract] [Full Text] [PDF]

				J. R. Piccotti, K. Li, S. Y. Chan, J. Ferrante, J. Magram, E. J. Eichwald, and D. K. Bishop Alloantigen-Reactive Th1 Development in IL-12-Deficient Mice J. Immunol., February 1, 1998; 160(3): 1132 - 1138. [Abstract] [Full Text] [PDF]